ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Rejection"

  • 2020 American Transplant Congress

    Reduced Dose of Mycophenolate Mofetil as Well as Preformed DSA Are Risk Factors Associated with the Development of Chronic Active Antibody Mediated Rejection after Kidney Transplantation: A Retrospective Case Control Study

    K. Shinoda1, H. Oguchi1, K. Nishikawa1, T. Yonekura1, M. Muramatsu1, T. Kawamura1, Y. Hamasaki1, T. Mikami2, K. Sakai1, S. Shishido1

    1Toho University Faculty of Medicine, Tokyo, Japan, 2Pathology, Toho University Faculty of Medicine, Tokyo, Japan

    *Purpose: The purpose of this study is to explore the risk factors associated with the development of chronic active antibody mediated rejection (CAAMR) after the…
  • 2020 American Transplant Congress

    Donor-Derived Cell-Free DNA May Not Discriminate Rejection in Kidney Transplant Recipients with a Prior Allograft in Place

    A. Vo, M. Gillespie, S. C. Jordan, A. Peng, R. Najjar, S. Sethi, K. Lim, N. Ammerman, E. Huang

    Cedars-Sinai, Los Angeles, CA

    *Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an injury biomarker discriminating rejection in kidney transplant (KTx) patients (pts). However, its performance when stratified by rejection risk…
  • 2020 American Transplant Congress

    Enough Initial Tacrolimus Blood Concentration is Crucial Even with Additional Everolimus in Corticosteroid Early Withdrawal Regimen for Kidney Transplant Recipients

    H. Sasaki1, T. Tanabe1, H. Higuchi1, T. Tsujimoto2, H. Harada1

    1Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan, 2Pharmacy, Sapporo City General Hospital, Sapporo, Japan

    *Purpose: Everolimus (EVR) in combination with low-dose calcineurin inhibitor has been demonstrated in clinical trials to have comparable efficacy in low immunological risk kidney transplant…
  • 2020 American Transplant Congress

    Case Series of Belatacept for Calcineurin Inhibitor Sparing after Lung Transplantation

    H. Patel, C. R. Ensor, R. D. Davis, L. Bogar, D. Colella, M. Kildea, J. Kim, A. Satterthwaite, D. Ventura, C. Gries

    AdventHealth, Orlando, FL

    *Purpose: Belatacept is a recombinant soluble fusion protein which selectively blocks T-cell co-stimulation. It received initial FDA approval for prophylaxis of organ rejection in Epstein-Barr…
  • 2020 American Transplant Congress

    Identification of Cell Types That Harbor Cytomegalovirus DNA in Acutely and Latently Infected Mice Spleen

    A. S. Maganti1, X. Liu2, M. Abecassis2

    1Illinois Math and Science Academy, Aurora, IL, 2Comprehensive Transplant Center, Northwestern University, Chicago, IL

    *Purpose: Cytomegalovirus (CMV) is a ubiquitous β‐herpesvirus that infects majority of humans. Primary CMV infection may be asymptomatic or manifests as a self‐limited febrile illness…
  • 2020 American Transplant Congress

    Effect of Simultaneous Presence of Anti-Blood Group A/B and -HLA Antibodies on Clinical Outcomes in Kidney Transplantation Across Positive Crossmatch: A Nationwide Cohort Study

    H. Kwon, Y. Ko, D. Han

    Department of General Surgery, Asan Medical Center, Seoul, Korea, Republic of

    *Purpose: ABO-incompatible (ABOi) and positive crossmatch (XM) kidney transplantation (KT) have been considered immunologically challenging. The present study analyzed the clinical outcomes in XM positive…
  • 2020 American Transplant Congress

    Targeting Th17: TIGIT as a Key Regulator of Tregs/Th17 Cells in Belatacept Resistant Rejection

    C. R. Hartigan, M. Wagener, M. L. Ford

    Emory University Transplant Center, Emory University, Atlanta, GA

    *Purpose: Belatacept resistant-rejection (BRR) is a major barrier to the widespread adoption of immune checkpoint blockade therapeutics in transplantation. Our lab has shown that patients…
  • 2020 American Transplant Congress

    The Banff Classification of Antibody-Mediated Rejection in Kidney Allografts: Comparison of Predictive Performance for Allograft Failure in Previous and Current Editions

    J. Callemeyn1, H. Ameye1, M. Coemans1, A. Senev2, E. Lerut3, B. Sprangers1, D. Kuypers1, M. Emonds2, M. Naesens1

    1Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium, 2Histocompatibility and Immunogenetics Laboratory, Red Cross-Flanders, Mechelen, Belgium, 3Imaging and Pathology, KU Leuven, Leuven, Belgium

    *Purpose: Since its introduction in 2001, the Banff classification for antibody-mediated rejection (ABMR) has undergone significant changes, mainly by inclusion of C4d-negative ABMR in 2013…
  • 2020 American Transplant Congress

    Single-Cell RNA Sequencing to Assess the Effect of IL-6 Receptor Blockade in Kidney Transplantation

    A. Zarinsefat, P. Rashmi, A. Da Silva, T. Sigdel, S. Chandran, Q. Tang, J. Ye, F. Vincenti, M. Sarwal

    University of California San Francisco, San Francisco, CA

    *Purpose: Prospective randomized study of IL-6R blockade with Tocilizumab for treatment of subclinical inflammation (SCI) in renal transplantation, reveals unique profiles of resting and stimulated…
  • 2020 American Transplant Congress

    Notch Signaling Inhibition via Blockade of Delta-Like Ligand 4 Prevents Co-Stimulation Blockade Resistant Allograft Rejection

    A. J. Matar, B. P. Lovasik, Y. Dong, D. A. Faber, J. Habib, C. A. Breeden, J. Regenold, A. Ghosh, A. Stephenson, W. H. Kitchens, A. B. Adams

    Surgery and Transplantation, Emory University, Atlanta, GA

    *Purpose: Co-stimulation blockade (CoB) has emerged as a promising immunosuppression strategy with the advent of Belatacept, a novel CTLA4-Ig fusion protein that blocks CD28-mediated T…
  • « Previous Page
  • 1
  • …
  • 45
  • 46
  • 47
  • 48
  • 49
  • …
  • 172
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences